Antisense HIV-1 therapy (Enzo Therapeutics)

N/A

Report date: 2022/12/23 18:07:07

Base Information

Drug NameAntisense HIV-1 therapy (Enzo Therapeutics)

Drug Alias Nametransduced autologous stem cell therapyanti-HIV antisense-oligonucleotide-expressing autologous CD34+ stem cellsHGTV-43

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionHIV replication inhibitors

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEnzo

China Registration ClassN/A

Develop Information

Active CompaniesEnzo

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A